# US 2021/0198353 A1 · Anti-tnf-alpha-antibodies and functional fragments thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198353 A1
- Document ID: US20210198353A1
- Status: Published application
- Kind: A1
- Application number: 16/085,506
- Filed: 2017-03-16
- Published: 2021-07-01
- Earliest claimed: 2016-03-17
- Assignees: Tillotts Pharma AG
- Applicants: Tillotts Pharma AG
- Inventors: Tea GUNDE; Sebastian MEYER; Esther Maria FURRER
- Web page: https://patentgrep.com/patent/US20210198353A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.

## Claims

### Claim 1

An antibody or a functional fragment thereof capable of binding to human tumor necrosis factor alpha (TNFα), wherein said antibody or functional fragment comprises:
i. a VL domain comprising a CDR1 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:1, a CDR2 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:2, and a CDR3 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:3, and
ii. a VH domain comprising a CDR1 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:4, a CDR2 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:5, and a CDR3 region having an amino acid sequence in accordance with the amino acid sequence as shown in SEQ ID NO:6.

### Claim 2 (depends on 1)

The antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises:
i. a VL domain comprising a CDR1 region having the amino acid sequence as shown in SEQ ID NO:7, a CDR2 region having the amino acid sequence as shown in SEQ ID NO:8, and a CDR3 region having the amino acid sequence as shown in SEQ ID NO:9, and
ii. a VH domain comprising a CDR1 region having the amino acid sequence as shown in SEQ ID NO:10, a CDR2 region having the amino acid sequence as shown in SEQ ID NO:11, and a CDR3 region having the amino acid sequence as shown in SEQ ID NO:12.

### Claim 3 (depends on 1, 2)

The antibody or functional fragment of claim 1 or 2, wherein said antibody or functional fragment:
(i) binds to human TNFα with a dissociation constant (KD) of less than 125 pM;
(ii) is cross-reactive with Macaca mulatta (Rhesus) TNFα and with Macaca fascicularis (Cynomolgus) TNFα;
(iii) has a greater potency to inhibit TNFα-induced apoptosis than infliximab, as determined by an L929 assay;
(iv) comprises a variable domain having a melting temperature, determined by differential scanning fluorimetry, of at least 70° C. and/or
(v) is capable of binding to human TNFαTrimer in a stoichiometry (antibody: TNFαTrimer) of at least 2.

### Claim 4 (depends on 1)

The antibody or functional fragment of claim 1, wherein said antibody binds to human TNFα with a KD of less than 50 pM.

### Claim 5 (depends on 1)

The antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a VH domain having the amino acid sequence as shown in SEQ ID NO:13.

### Claim 6 (depends on 1)

The antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a VL domain having an amino acid sequence selected from SEQ ID NO:14 and SEQ ID NO:54.

### Claim 7 (depends on 1)

The antibody or functional fragment of claim 1, wherein said antibody or functional fragment is a single-chain variable fragment (scFv).

### Claim 8 (depends on 7)

The antibody or functional fragment of claim 7, wherein said scFv has the amino acid sequence as shown in SEQ ID NO:15 or SEQ ID NO:55.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein said antibody is an immunoglobulin G (IgG).

### Claim 10 (depends on 8)

An antibody or functional fragment thereof, wherein said antibody or functional fragment binds essentially the same epitope as the antibody or functional fragment of claim 8.

### Claim 11 (depends on 1)

The antibody or functional fragment of claim 1, wherein the sum of (i) the number of amino acids in framework regions I, II, and III of the variable light domain of said antibody or functional fragment that are different from the respective human Vκ1 consensus sequences SEQ ID NOs: 56, 57, and 58, and (ii) the number of amino acids in framework region IV of the variable light domain of said antibody or functional fragment that are different from the most similar human λ germline-based sequence selected from SEQ ID NOs: 59, 60, 61, and 62, is less than 7.

### Claim 12 (depends on 1)

The antibody or functional fragment of claim 1, wherein the framework regions I, II, and to III of the variable light domain of said antibody or functional fragment consist of human Vκ1 consensus sequences with SEQ ID NOs:56, 57, and 58, respectively, and framework region IV consists of a λ germline-based sequence selected from among SEQ ID NOs:59, 60, 61, and 62.

### Claim 13 (depends on 1)

A nucleic acid encoding the antibody or functional fragment of claim 1.

### Claim 14 (depends on 13)

A vector or plasmid comprising the nucleic acid of claim 13.

### Claim 15 (depends on 13)

A cell comprising the nucleic acid of claim 13 or a vector or plasmid comprising the nucleic acid of claim 13.

### Claim 16 (depends on 1)

A method of preparing the antibody or functional fragment of claim 1, comprising the steps of: culturing the as cell comprising a plasmid comprising said nucleic acid a medium under conditions that allow expression of the nucleic acid encoding the antibody or functional fragment, and recovering the antibody or functional fragment from the cells or from the medium.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the antibody or functional fragment of claim 1 in combination with an optional and optionally a pharmaceutically acceptable carrier and/or excipient.

### Claim 18 (depends on 17)

A method of treating an inflammatory disorder or a TNFα-related disorder in a subject in need thereof, said method comprising the step of administering the pharmaceutical composition of claim 17 to said subject.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said inflammatory disorder is an inflammatory disorder of the gastrointestinal tract.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said inflammatory disorder of the gastrointestinal tract is inflammatory bowel disease.

### Claim 21 (depends on 19)

The method according to claim 19, wherein said inflammatory disorder of the gastrointestinal tract is Crohn's disease or ulcerative colitis.

### Claim 22 (depends on 1)

The antibody or functional fragment of claim 1, wherein the sum of (i) the number of amino acids in framework regions I, II, and III of the variable light domain of said antibody or functional fragment that are different from the respective human Vκ1 consensus sequences SEQ ID NOs: 56, 57, and 58, and (ii) the number of amino acids in framework region IV of the variable light domain of said antibody or functional fragment that are different from the most similar human λ germline-based sequence selected from SEQ ID NOs: 59, 60, 61, and 62, is less than 4.
